The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.
暂无分享,去创建一个
T. Hagemann | F. Balkwill | H. Kulbe | Julia L. Wilson | D. Gould | A. Ayhan | Frances Balkwill | Richard B. Thompson | Hagen Kulbe | Richard Thompson | Julia L Wilson | Stephen Robinson | Thorsten Hagemann | Rewas Fatah | David Gould | Ayse Ayhan | Stephen C. Robinson | R. Fatah | Rewas Fatah
[1] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[2] T. Hagemann,et al. Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK1 , 2005, The Journal of Immunology.
[3] Fan Zhang,et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.
[4] T. Hagemann,et al. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. , 2005, Cancer research.
[5] Li Yan,et al. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. , 2006, European journal of cancer.
[6] P. Allavena,et al. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. , 2004, European journal of cancer.
[7] P. Szlosarek,et al. Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .
[8] P. Szlosarek,et al. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. , 2003, The Lancet. Oncology.
[9] P. Szlosarek,et al. Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium , 2006, Molecular Cancer Therapeutics.
[10] A. Harris,et al. A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[11] Robert J. Moore,et al. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. , 2002, Oncogene.
[12] P. Szlosarek,et al. Tumour necrosis factor-α as a tumour promoter , 2006 .
[13] S. Mok,et al. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. , 2002, Journal of the National Cancer Institute.
[14] G. Stamp,et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.
[15] R. Bernards,et al. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.
[16] L. Karabon,et al. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity , 2000, British Journal of Cancer.
[17] D. Hicklin,et al. Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.
[18] G. Jayson,et al. Regulation of Fibroblast Growth Factor-2 Activity by Human Ovarian Cancer Tumor Endothelium , 2005, Clinical Cancer Research.
[19] S. Biesterfeld,et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up , 2005, International Journal of Gynecologic Cancer.
[20] Lieve Moons,et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.
[21] D. Lauffenburger,et al. The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade , 2006, Cell.
[22] W. Fiers,et al. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer , 1989, International journal of cancer.
[23] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[24] P. Neven,et al. Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia , 2005, International Journal of Gynecologic Cancer.
[25] F. Balkwill,et al. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours , 2001, British Journal of Cancer.
[26] W. Foulkes,et al. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. , 1993, The Journal of clinical investigation.
[27] J. da Silva,et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.
[28] G. Kollias,et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.
[29] John Condeelis,et al. Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.
[30] D. Phillips,et al. Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway , 2002, Oncogene.
[31] M. Gorospe,et al. von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays , 2003, Molecular and Cellular Biology.
[32] T. Calandra,et al. Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.